Placeholder Banner

Sarbanes-Oxley in Financial Services Compromise: Sarbanes-Oxley 404(b) Legislative Text in the Wall Street Reform and Consumer Protection Act of 2009

March 10, 2016

BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies. The provision would permanently exempt companies with market capitalizations of $75 million or less from Section 404(b) of the Sarbanes-Oxley Act of 2002 (SOX). BIO has advocated strongly on behalf of this provision, which would become law if the current compromise passes both chambers of Congress. The House passed the financial regulatory reform compromise on June 30 by a vote of 237-192 and the Senate is expected to vote on the measure after the July 4th recess.

Download Full Comments Below
404(b) Perm Exemption House-Senate Comprise
Read the document
Discover More
Innovative breakthroughs can secure our nation’s food supply by reducing greenhouse gas emissions throughout agricultural supply chains; strengthening producers’ resiliency to climate change while increasing production; and tackling hunger and…
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…